COVID-19 spike variants antigen Recombinant 2019-nCoV(SARS-CoV-2) (South African variant 501Y.V2 lineage,B.1.351) Spike Protein RBD(K417N, E484K and N501Y mutant)

COVID-19 recombinant SARS-CoV2 (2019 nCoV coronavirus)antigen:
Recombinant 2019-nCoV(SARS-CoV-2) (South African variant 501Y.V2 lineage, B.1.351)
Spike Protein RBD(K417N, E484K and N501Y mutant)
Suitable for variants of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-22 vaccines and therapeutic antibodies.
Validated in functional ELISA, other immunoassays, The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.
Spike mutant variant of SARS-COV-2 (2019nCOV) 501Y.V2 lineage spread in South African (B.1.351)

The world is in midst of the COVID-19 pandemic. Recently a new SARS-CoV-2 (2019nCOV)lineage (501Y.V2), characterised by eight lineage-defining mutations in the spike protein (excluding D614G mutation), including three at important residues in the receptor-binding domain (K417N, E484K and N501Y), represents increased transmissibility. This lineage emerged in South Africa and spread rapidly, becoming within weeks the dominant lineage in the Eastern Cape and Western Cape Provinces of South Africa.

Mutations of Spike protein in SARS-COV-2 (2019nCOV) 501Y.V2 lineage spread in South African (B.1.351)
Three of the spike mutations are at key residues in the RBD (N501Y, E484K and K417N), three are in the N-terminal domain (L18F, D80A and D215G) and one is in loop 2 (A701V). Deletion of three amino acids at L242-244L is disputed with a L242H mutation1.
Spike Mutation in SARS-COV-2 (2019nCOV) 501Y.V2 lineage Spike-S1 Subunit
N Terminal L18F
D8OA
D215G
Spike-S1 Subunit L242-244 deletion disputed with a L242H mutation
Spike-S1 Subunit R246I
Spike-RBD K417N Important residues mutation
E484K
N501Y
Spike-S1 Subunit D614G A popular mutation in different new SARS-CoV-2 lineage
Spike-S2 Subunit A701V

Figure. Amino acid changes in the spike region of the 190 S501Y.V2 genomes1.

GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) 501Y.V2 lineage(B.1.351)
Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) S501Y.V2 lineage, which will meet the evaluation of the efficacy of COVID19 vaccines and therapeutic antibodies.
GM-2019nCoV-PSV18 Spike E484K mutant SARS-CoV-2(2019nCoV) Pseudotyped virus production and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV19 Spike RBD triple mutant (K417N, E484K and N501Y) SARS-CoV-2(2019nCoV) Pseudotyped virus production and Pseudovirus Based Neutralization Assay
GM-2019nCoV-PSV20 Spike whole mutant SARS-CoV-2(2019nCoV) 501Y.V2 lineage Pseudotyped virus production and Pseudovirus Based Neutralization Assay

GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) S501Y.V2 lineage (B.1.351)
GeneMedi designed a mammalian expression codon-optimized spike mutation/deletion variant vector for COVID-19 SARS-COV-2 (2019nCOV) S501Y.V2 lineage.

GMV-V-2019nCoV-107 pGM-2019nCoV-Spike(S1+S2)-E484K mutation(501Y.V2 lineage) pcDNA3.1(+) No tag coden optimized
for mamamlian
GMV-V-2019nCoV-108 Ad-2019nCoV-Spike(S1+S2)-E484K mutation(501Y.V2 lineage) Pre-made adenovirus C-3FLAG coden optimized
for mamamlian
GMV-V-2019nCoV-109 pGM-Spike(S1+S2)RBD triple mutation of 501Y.V2 lineage(K417N, E484K and N501Y) pcDNA3.1(+) No tag coden optimized
for mamamlian
GMV-V-2019nCoV-110 Ad-Spike(S1+S2)RBD triple mutation of 501Y.V2 lineage(K417N, E484K and N501Y) Pre-made adenovirus C-3FLAG coden optimized
for mamamlian
GMV-V-2019nCoV-111 pGM-Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) 501Y.V2 lineage pcDNA3.1(+) No tag coden optimized
for mamamlian
GMV-V-2019nCoV-112 Ad-Spike (S1+S2) whole mutation variant of SARS-CoV-2(2019nCoV) 501Y.V2 lineage Pre-made adenovirus C-3FLAG coden optimized
for mamamlian